FlowCellect™ Bivariate Cell Cycle Kit for DNA Replication Analysis
Millipore’s FlowCellect™ Bivariate Cell Cycle Kit for DNA Replication Analysis is designed to investigate cells undergoing replication in S-phase of the cell cycle with high accuracy and confidence in flow cytometry applications. The kit includes a directly conjugated Anti-BrdU Alexa Fluor® 488 conjugate plus a DNA dye (Propidium Iodide) which allows the researcher to perform bivariate analysis to distinguish cells in two dim…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Millipore’s FlowCellect™ Bivariate Cell Cycle Kit for DNA Replication Analysis is designed to investigate cells undergoing replication in S-phase of the cell cycle with high accuracy and confidence in flow cytometry applications.
The kit includes a directly conjugated Anti-BrdU Alexa Fluor® 488 conjugate plus a DNA dye (Propidium Iodide) which allows the researcher to perform bivariate analysis to distinguish cells in two dimensions without the need of software modules for data interpretation. Flow cytometry allows the simultaneous measurement of incorporated BrdU as well as the DNA content on a single cell level. In this way, the cohort of labeled cells can be followed through the cell cycle.
The kit includes an optimized protocol with all of the necessary components to provide the researcher a true “plug and play” design for their research when studying DNA replication and its relation to cell proliferation and cancer.
The kit includes a BrdU precursor to allow for BrdU measurement by the conjugated antibody and an RNase reagent to ensure that the PI intensity is directly proportional to DNA content only.
This immunocytochemical method is very sensitive, and it offers an assay to screen in vivo inhibitors involved in the S-phase transition by flow cytometry. It is important to determine the biological characteristics of certain cancers, not only to evaluate their malignant potentials but also to decide on the most effective anticancer therapies.